Neoantigens Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Publication Month: May 2021 | Report Code: TIPRE00021781 | No. of Pages: 151 | Category: Pharmaceuticals | Status: Published

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The neoantigens market was valued at US$ 2,71,428.57 thousand in 2023, and it is projected to reach US$ 10,54,783.54 thousand by 2028; it is expected to grow at a CAGR of 31.2% from 2023 to 2028.

 

Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.

The neoantigens market is segmented based on treatment, therapeutic specialty, and geography. Based on geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the neoantigens market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world. It also includes COVID-19 impact analysis across all the regions. It is estimated that the market is likely to have a steady growth rate during the forecast period.

 

Lucrative Regions for Neoantigens Market

Get more information on this report :


 

Market Insights

Developments in Neoantigen Vaccines Against Cancer

Developments in biotechnology have led to rise in acceptance for immunotherapy, further driving its use in personalized medicines. Immunotherapy is widely used to treat cancer; a few the immunotherapy procedures involve the use of neoantigens, the antigens present on the surface of cancer cells. Therefore, applications of neoantigens are being widely studied to treat cancer. The uniqueness of neoantigens allows researchers to identify patients’ immune system and find antigens to target cancer cells without disturbing healthy cells.

The developments in immunotherapy caught pace after 2015, when the first clinical trial of neoantigen vaccine was performed. In 2017, two additional clinical trial studies were published by Neon Therapeutics that proved the efficacy of neoantigen vaccine treat melanoma (skin cancer) in humans. The positive results of clinical trials have attracted various startups to discover and develop neoantigen-based cancer therapeutics. Many companies have shown interest in the development of neoantigens. Following are few examples of companies involved in the development of neoantigens.

  • BioNTech SE is a German company operating in the neoantigen vaccines market. BioNTech SE has developed Individualized Vaccines Against Cancer (IVAC) Mutanome platform that engineer RNA molecules to produce customized neoantigen vaccine. The clinical trials for IVAC that target triple negative breast cancer, multiple tumor types, and melanoma are pending.
  • The ATLAS platform of Genocea Biosciences uses an ex-vivo method to develop neoantigen vaccines. Genocea Biosciences has raised ~US$ 91 million funds from investors such as Polaris Partners, GlaxoSmithKline, and Johnson & Johnson Innovation to develop its neoantigen cancer vaccine—GEN-009. Currently in the Phase 1a/2 clinical trial, the vaccine is designed to treat melanoma, lung cancer, and carcinomas.
  • Gritstone Oncology uses its AI platform—EDGE—to develop neoantigen vaccines using an in-silico approach. The company has developed two products GRANITE-001 and SLATE-001. GRANITE-001 is designed as an individual treatment based on patient’s specific tumor type, whereas SLATE-001 is formulated as a common neoantigen vaccine that can be used for multiple patients showing similar neoantigen.
  • Agenus Inc. has developed AutoSynVax (ASV) neoantigen vaccine that is administered with an adjuvant QS-21 Stimulon to treat solid tumors. At present ASV is in the Phase 1 clinical trial in USA.
  • Since 2016, Moderna, Inc. is involved in clinical trials for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda by Merck. In November 2020, Moderna, Inc. published updates about its cancer vaccines stating that administrating mRNA-4157 in combination with Keytruda is well tolerated at all dose levels and has produced responses in patients.

Such developments in the neoantigen vaccines against cancer are fuelling the market growth.

 

Treatment-Based Insights

Based on treatment, the neoantigens market is segmented into combination therapy and mono therapy. In 2023, the combination therapy segment is estimated to have a larger share of the market. However, the mono therapy segment is expected to have a faster growth during the forecast period.

 

Global Neoantigens Market, by Treatment – 2020 & 2028

Get more information on this report :


 

Therapeutic Specialty -Based Insights

Based on therapeutic specialty, the neoantigens market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market and is expected to grow at the fastest rate in the coming years.

 

Strategic Insights

Inorganic strategies were highly adopted by the market players to meet the changing customer demand and maintain their improved services. For instance, in January 2021, Genocea Announces Cancer Discovery Publication owing to the benefits of neoantigen identification using the ATLAS Platform. This discovery strengthens neoantigen immunotherapies by theoretically ensuring that they target the correct neoantigens while removing Inhibigens.

 

By Treatment

  • Combination Therapy
  • Mono Therapy

By Therapeutic Specialty

  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumors
  • Urinary System Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

 

Company Profiles

  • Achilles Therapeutics plc
  • Advaxis, Inc.
  • Frame Cancer Therapeutics
  • Genocea, Gradalis, Inc.
  • Gritstone Oncology
  • Immunicum AB
  • Medigene AG
  • Ziopharm Oncology, Inc.
  • Moderna, Inc.

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

1.3.1        Neoantigens Market – By Treatment

1.3.2        Neoantigens Market – By Therapeutic Specialty

1.3.3        Neoantigens Market– By Geography

2.             Neoantigens Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             Neoantigens Market– Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1        North America PEST Analysis

4.2.2        Europe PEST Analysis

4.2.3        Asia Pacific PEST Analysis

4.2.4        Middle East and Africa PEST Analysis

4.2.5        South and Central America PEST Analysis

4.3       Expert Opinion

5.             Neoantigens Market – Key Market Dynamics

5.1       Market Drivers

5.1.1        Developments in Neoantigen Vaccines Against Cancer

5.1.2        Increasing Prevalence of Cancer

5.2       Market Restraints

5.2.1        Possible Side Effects Associated with Neoantigen Vaccines

5.3       Market Opportunities

5.3.1        Application of Next-generation Sequencing for Neoantigen Identification

5.4       Future Trends

5.4.1        Use of AI in Neoantigen Vaccine Development

5.5       Impact Analysis

6.             Neoantigens Market – Global Analysis

6.1       Global Neoantigens Market Revenue Forecast and Analysis

6.2       Global Neoantigens Market, By Geography - Forecast and Analysis

6.3       Key Players

7.             Neoantigens Market Analysis – By Treatment

7.1       Overview

7.2       Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

7.3       Combination Therapy

7.3.1        Overview

7.3.2        Combination Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

7.4       Mono Therapy

7.4.1        Overview

7.4.2        Mono Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.             Neoantigens Market Analysis – By Therapeutic Specialty

8.1       Overview

8.2       Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

8.3       Gastrointestinal Cancer

8.3.1        Overview

8.3.2        Gastrointestinal Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.4       Lung Cancer

8.4.1        Overview

8.4.2        Lung Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.5       Solid Tumors

8.5.1        Overview

8.5.2        Solid Tumors: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.6       Urinary System Cancers

8.6.1        Overview

8.6.2        Urinary System Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.7       Melanoma

8.7.1        Overview

8.7.2        Melanoma: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.8       Head and Neck Cancers

8.8.1        Overview

8.8.2        Head and Neck Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.9       Others

8.9.1        Overview

8.9.2        Others: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

9.             Neoantigens Market – Geographical Analysis

9.1       North America: Neoantigens Market Revenue and Forecast to 2028

9.1.1        Overview

9.1.2        North America: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3        North America: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.4        North America: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.5        North America: Neoantigens Market, by Country, 2023 & 2028 (%)

9.1.6        US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.1      US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.2      US: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.6.3      US: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.7        Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.1      Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.2      Canada: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.7.3      Canada: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.8        Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.1      Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.2      Mexico: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.8.3      Mexico: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.2       Europe: Neoantigens Market

9.2.1        Overview

9.2.2        Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.3        Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.4        Europe: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028  (USD Thousand)

9.2.5        Europe: Neoantigens Market, by Country, 2023 & 2028(%)

9.2.6        Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.6.1      Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.6.2      Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.6.3      Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.2.7        France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.7.1      France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.7.2      France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.7.3      France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.2.8        UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.8.1      UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.8.2      UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.8.3      UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

9.2.9        Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.9.1      Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.9.2      Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.9.3      Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.2.10     Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.10.1    Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.10.2    Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.10.3    Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.2.11     Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.11.1    Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.2.11.2    Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.2.11.3    Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.3       Asia Pacific: Neoantigens Market

9.3.1        Overview

9.3.2        Asia Pacific: Neoantigens Market - Revenue and Forecast to 2028 (USD Thousand)

9.3.3        Asia Pacific: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.3.4        Asia Pacific: Neoantigens Market, by Therapeutic Application – 2023–2028 (USD Thousand)

9.3.5        Asia Pacific: Neoantigens Market, by Country, 2023 & 2028 (%)

9.3.6        China: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.6.1      China: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.6.2      China: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.3.6.3      China: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.3.7        Japan: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.7.1      Japan: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.7.2      Japan: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.3.7.3      Japan: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.3.8        India: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.8.1      India: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.8.2      India: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.3.8.3      India: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.3.9        South Korea: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.9.1      South Korea: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.9.2      South Korea: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.3.9.3      South Korea: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.3.10     Australia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.10.1    Australia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.10.2    Australia: Neoantigens Market, by Treatment, 2019–2028 (USD Thousand)

9.3.10.3    Australia: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.3.11     Rest of Asia-Pacific: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.11.1    Rest of Asia-Pacific: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.3.11.2    Rest of Asia-Pacific: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.3.11.3    Rest of Asia-Pacific: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.4       Middle East and Africa: Neoantigens Market

9.4.1        Overview

9.4.2        Middle East and Africa: Neoantigens Market - Revenue and Forecast to 2028 (USD Thousand)

9.4.3        Middle East and Africa: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.4.4        Middle East and Africa: Equipment Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.4.5        Middle East and Africa: Neoantigens Market, by Country, 2020& 2028 (%)

9.4.6        UAE: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.6.1      UAE: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.6.2      UAE: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.4.6.3      UAE: Equipment Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.4.7        Saudi Arabia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.7.1      Saudi Arabia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.7.2      Saudi Arabia: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.4.7.3      Saudi Arabia: Equipment Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.4.8        South Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.8.1      South Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.8.2      South Africa: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.4.8.3      South Africa: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.4.9        Rest of Middle East and Africa: Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.4.9.1      Rest of Middle East and Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.4.9.2      Rest of Middle East and Africa Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.4.9.3      Rest of Middle East and Africa: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.5       South and Central America: Neoantigens Market

9.5.1        Overview

9.5.2        South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)

9.5.3        South and Central America: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.5.4        South and Central America: Neoantigens Market, by Therapeutic Application, 2023–2028  (USD Thousand)

9.5.5        South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)

9.5.6        Brazil: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.5.6.1      Brazil: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.5.6.2      Brazil: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.5.6.3      Brazil: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.5.7        Argentina: Neoantigens Market – Revenue and Forecast to 2027 (USD Thousand)

9.5.7.1      Argentina: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.5.7.2      Argentina: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.5.7.3      Argentina: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

9.5.8        Rest of South and Central America: Neoantigens Market – Revenue and Forecast to 2027 (USD Thousand)

9.5.8.1      Rest of South and Central America: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.5.8.2      Rest of South and Central America: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.5.8.3      Rest of South and Central America: Neoantigens Market, by Therapeutic Application, 2023–2028 (USD Thousand)

10.          Impact Of COVID-19 Pandemic on Global Neoantigens Market

10.1    North America: Impact Assessment of COVID-19 Pandemic

10.2    Europe: Impact Assessment of COVID-19 Pandemic

10.3    Asia-Pacific: Impact Assessment of COVID-19 Pandemic

10.4    Middle East and Africa: Impact Assessment of COVID-19 Pandemic

10.5    South and Central America: Impact Assessment of COVID-19 Pandemic

11.          Neoantigens Market–Industry Landscape

12.          Company Profiles

12.1    Achilles Therapeutics plc

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2    Advaxis, Inc.

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3    Frame Cancer Therapeutics

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4    Genocea

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5    Gradalis, Inc.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6    Gritstone Oncology

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7    Immunicum AB

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8    Medigene AG

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9    Ziopharm Oncology, Inc.

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Products and Services

12.9.4     Financial Overview

12.9.5     SWOT Analysis

12.9.6     Key Developments

12.10 Moderna, Inc.

12.10.1   Key Facts

12.10.2   Business Description

12.10.3   Products and Services

12.10.4   Financial Overview

12.10.5   SWOT Analysis

12.10.6   Key Developments

13.          Appendix

13.1    About the Insight Partners

13.2    Glossary of Terms

LIST OF TABLES

Table 1.             New Cancer Cases Registered Worldwide, 2020

Table 2.             North America: Neoantigens Market, by Treatment – Revenue and Forecast to 2028(USD Thousand)

Table 3.             North America: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 4.             US: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 5.             US: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 6.             Canada: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 7.             Canada: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 8.             Mexico: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 9.             Mexico: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 10.          Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 11.          Europe: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 12.          Incidence, Mortality and Prevalence by cancer site, 2020, Germany

Table 13.          Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 14.          Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 15.          Incidence, Mortality and Prevalence by cancer site, 2020, France

Table 16.          France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 17.          France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 18.          UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 19.          UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

Table 20.          Incidence, Mortality and Prevalence by cancer site, 2020, Italy

Table 21.          Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 22.          Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 23.          Incidence, Mortality and Prevalence by cancer site, 2020, Spain

Table 24.          Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 25.          Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 26.          Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 27.          Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028  (USD Thousand)

Table 28.          Asia Pacific Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 29.          Asia Pacific Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028  (USD Thousand)

Table 30.          China Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 31.          China Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 32.          Japan Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 33.          Japan Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 34.          India Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 35.          India Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 36.          South Korea Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 37.          South Korea Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028  (USD Thousand)

Table 38.          Incidence, Mortality and Prevalence by Cancer Site, Australia, 2020

Table 39.          Australia Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 40.          Australia Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 41.          Rest of Asia-Pacific: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 42.          Rest of Asia-Pacific: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 43.          Middle East and Africa Neoantigens Market, by Treatment– Revenue and Forecast to 2028(USD Thousand)

Table 44.          Middle East and Africa Equipment Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 45.          UAE Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 46.          UAE Equipment Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 47.          Saudi Arabia Neoantigens Market, by Treatment– Revenue and Forecast to 2028 (USD Thousand)

Table 48.          Saudi Arabia Equipment Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 49.          South Africa Neoantigens Market, by Treatment– Revenue and Forecast to 2028 (USD Thousand)

Table 50.          South Africa Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 51.          Rest of Middle East and Africa Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 52.          Rest of Middle East and Africa Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 53.          South and Central America Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 54.          South and Central America Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 55.          Brazil Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 56.          Brazil Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 57.          Argentina Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 58.          Argentina Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028  (USD Thousand)

Table 59.          Rest of South and Central America Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 60.          Rest of South and Central America Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 61.          Glossary of Terms, Neoantigens Market

 

 

LIST OF FIGURES

Figure 1.           Neoantigens Market Segmentation

Figure 2.           Neoantigens Segmentation, By Region

Figure 3.           Global Neoantigens Market Overview

Figure 4.           Combination Therapy Segment Holds Largest Share of Neoantigens Market

Figure 5.           APAC to Show Remarkable Growth During Forecast Period

Figure 6.           Global Neoantigens Market, by Geography (US$ Thousand)

Figure 7.           Global Neoantigens Market – Leading Country Markets (US$ Thousand)

Figure 8.           Global Neoantigens Market, Industry Landscape

Figure 9.           North America: PEST Analysis

Figure 10.        Europe: PEST Analysis

Figure 11.        Asia Pacific: PEST Analysis

Figure 12.        Middle East and Africa: PEST Analysis

Figure 13.        South and Central America: PEST Analysis

Figure 14.        Expert Opinion

Figure 15.        Neoantigens Market Impact Analysis of Drivers and Restraints

Figure 16.        Global Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028

Figure 17.        Global Neoantigens Market – By Geography Forecast and Analysis – 2020- 2028

Figure 18.        Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

Figure 19.        Combination Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 20.        Mono Therapy: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 21.        Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

Figure 22.        Gastrointestinal Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 23.        Lung Cancer: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 24.        Solid Tumors: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 25.        Urinary System Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 26.        Melanoma: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 27.        Head and Neck Cancers: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 28.        Others: Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 29.        North America: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 30.        North America: Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)

Figure 31.        North America: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 32.        US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 33.        Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 34.        Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 35.        Europe: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 36.        Europe: Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)

Figure 37.        Europe: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 38.        Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 39.        France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 40.        UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 41.        Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 42.        Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 43.        Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 44.        Asia Pacific: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 45.        Asia Pacific Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)

Figure 46.        Asia Pacific: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 47.        China: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 48.        Japan: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 49.        India: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 50.        South Korea: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 51.        Australia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 52.        Rest of Asia-Pacific: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 53.        Middle East and Africa: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 54.        Middle East and Africa Neoantigens Market Revenue and Forecast to 2028 (USD Thousand)

Figure 55.        UAE: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 56.        Saudi Arabia: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 57.        South Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 58.        Rest of Middle East and Africa: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 59.        South and Central America: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 60.        South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 61.        South and Central America: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 62.        Brazil: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 63.        Argentina: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 64.        Rest of South and Central America: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 65.        Impact of COVID-19 Pandemic in North American Country Markets

Figure 66.        Impact of COVID-19 Pandemic in European Country Markets

Figure 67.        Impact of COVID-19 Pandemic in Asia Pacific Country Markets

Figure 68.        Impact Of COVID-19 Pandemic in Middle East and Africa Market

Figure 69.        Impact Of COVID-19 Pandemic in South and Central America Market

The List of Companies - Neoantigens Market

  1. Achilles Therapeutics plc
  2. Advaxis, Inc.
  3. Frame Cancer Therapeutics
  4. Genocea
  5. Gradalis, Inc.
  6. Gritstone Oncology
  7. Immunicum AB
  8. Medigene AG
  9. Ziopharm Oncology, Inc.
  10. Moderna, Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the neoantigens market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global neoantigens market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
TIPRE00021781
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Frequently Asked Questions

Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.

Key factors that are driving growth of the market are developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.

Several companies into clinical trial phases for their respective neoantigens. It is expected that by 2023, companies will commercialize their products in the market. In addition, it is expected that the cost of neoantigens will be much higher than cancer vaccines.

Pricing